Regen BioPharma, Inc. (OTCMKTS:RGBP – Get Free Report) was the target of a significant increase in short interest in September. As of September 15th, there was short interest totaling 42 shares. Based on an average trading volume of 12,600,992 shares, the short-interest ratio is presently 0.0 days.
Regen BioPharma Price Performance
RGBP remained flat at $0.00 on Tuesday. The company had a trading volume of 2,764,037 shares, compared to its average volume of 16,746,252. Regen BioPharma has a 1 year low of $0.00 and a 1 year high of $0.04.
Regen BioPharma Company Profile
Regen BioPharma, Inc is a biotechnology company focused on developing regenerative medicine and immunotherapy technologies. Its research has included approaches intended to regulate stem-cell activity, restore damaged tissue, and modify immune responses associated with cancer and other diseases.
The company has publicly described several investigational programs, including HemaXellerate, a stem-cell-based approach studied for potential use in bone-marrow failure disorders; dCellVax, an experimental cancer-immunotherapy platform; and research involving NR2F6, an immune-regulatory target.
See Also
- Five stocks we like better than Regen BioPharma
- Bottlenecking the Future: TSMC Prices Out the Competition
- Fervo Energy Hits Geothermal Milestone: Will It Matter For The Stock?
- Tesla’s Semi Is Finally Here—But Will It Move the Stock?
- 5 Stocks Showing Why Pricing Power Matters More Than Government Money
Receive News & Ratings for Regen BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regen BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
